These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1126 related articles for article (PubMed ID: 15602019)

  • 1. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
    Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T; Shea T; Yanovich S; Hansen K; Noga S; McCarty J; LeMaistre CF; Sung EC; Blazar BR; Elhardt D; Chen MG; Emmanouilides C
    N Engl J Med; 2004 Dec; 351(25):2590-8. PubMed ID: 15602019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support.
    Radtke ML; Kolesar JM
    J Oncol Pharm Pract; 2005 Sep; 11(3):121-5. PubMed ID: 16390600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting.
    Stiff PJ; Emmanouilides C; Bensinger WI; Gentile T; Blazar B; Shea TC; Lu J; Isitt J; Cesano A; Spielberger R
    J Clin Oncol; 2006 Nov; 24(33):5186-93. PubMed ID: 16391299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
    Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
    J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
    Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis.
    McDonnell AM; Lenz KL
    Ann Pharmacother; 2007 Jan; 41(1):86-94. PubMed ID: 17190850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.
    Vadhan-Raj S; Trent J; Patel S; Zhou X; Johnson MM; Araujo D; Ludwig JA; O'Roark S; Gillenwater AM; Bueso-Ramos C; El-Naggar AK; Benjamin RS
    Ann Intern Med; 2010 Sep; 153(6):358-67. PubMed ID: 20855800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation.
    Freytes CO; Ratanatharathorn V; Taylor C; Abboud C; Chesser N; Restrepo A; Arango J; Odenheimer D
    Clin Cancer Res; 2004 Dec; 10(24):8318-24. PubMed ID: 15623608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study.
    Le QT; Kim HE; Schneider CJ; Muraközy G; Skladowski K; Reinisch S; Chen Y; Hickey M; Mo M; Chen MG; Berger D; Lizambri R; Henke M
    J Clin Oncol; 2011 Jul; 29(20):2808-14. PubMed ID: 21670453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
    Nasilowska-Adamska B; Rzepecki P; Manko J; Czyz A; Markiewicz M; Federowicz I; Tomaszewska A; Piatkowska-Jakubas B; Wrzesien-Kus A; Bieniaszewska M; Duda D; Szydlo R; Halaburda K; Szczepinski A; Lange A; Hellman A; Robak T; Skotnicki A; Jedrzejczak WW; Walewski J; Holowiecki J; Komarnicki M; Dmoszynska A; Warzocha K; Marianska B
    Bone Marrow Transplant; 2007 Nov; 40(10):983-8. PubMed ID: 17846600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial.
    Henke M; Alfonsi M; Foa P; Giralt J; Bardet E; Cerezo L; Salzwimmer M; Lizambri R; Emmerson L; Chen MG; Berger D
    J Clin Oncol; 2011 Jul; 29(20):2815-20. PubMed ID: 21670447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
    J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.
    Langner S; Staber P; Schub N; Gramatzki M; Grothe W; Behre G; Rabitsch W; Urban C; Linkesch W; Neumeister P
    Bone Marrow Transplant; 2008 Aug; 42(4):275-9. PubMed ID: 18500368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation.
    Kim KI; Kim JW; Lee HJ; Kim BS; Bang SM; Kim I; Oh JM; Yoon SS; Lee JS; Park S; Kim BK
    Am J Hematol; 2013 Feb; 88(2):107-12. PubMed ID: 23225026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.
    Jagasia MH; Abonour R; Long GD; Bolwell BJ; Laport GG; Shore TB; Durrant S; Szer J; Chen MG; Lizambri R; Waller EK
    Bone Marrow Transplant; 2012 Oct; 47(10):1350-5. PubMed ID: 22327131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palifermin and chemotherapy-induced oral mucositis.
    Palmieri C; Vigushin D
    N Engl J Med; 2005 Mar; 352(12):1264-5; author reply 1264-5. PubMed ID: 15791703
    [No Abstract]   [Full Text] [Related]  

  • 17. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
    Rosen LS; Abdi E; Davis ID; Gutheil J; Schnell FM; Zalcberg J; Cesano A; Gayko U; Chen MG; Clarke S
    J Clin Oncol; 2006 Nov; 24(33):5194-200. PubMed ID: 17075109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palifermin: new drug. Prevention of oral mucositis: inappropriate evaluation.
    Prescrire Int; 2007 Aug; 16(90):135-8. PubMed ID: 17724832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palifermin (Kepivance) for myelotoxic-therapy-related mucositis.
    Med Lett Drugs Ther; 2005 Apr; 47(1207):36. PubMed ID: 15843784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palifermin and chemotherapy-induced oral mucositis.
    Köstler WJ; Hejna M; Zielinski CC
    N Engl J Med; 2005 Mar; 352(12):1264-5; author reply 1264-5. PubMed ID: 15791702
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 57.